# US 2021/0171467 A1 · Redox substrates for leukocyte esterase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171467 A1
- Document ID: US20210171467A1
- Status: Published application
- Kind: A1
- Application number: 16/762,686
- Filed: 2018-11-08
- Published: 2021-06-10
- Earliest claimed: 2017-11-08
- Assignees: Board of Regents, The University of Texas System
- Inventors: Waldemar GORSKI; Stanton MCHARDY; Douglas HANSON; Travis MENARD; Andrew FLEISCHMAN
- Web page: https://patentgrep.com/patent/US20210171467A1

## CPC

- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07D 213/71: to which a second hetero atom is attached
- G01N 27/27: Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Certain embodiments are directed hydrophilic redox substrates for leukocyte esterase (LE). In certain aspects a hydrophilic redox leukocyte esterase substrate or a small molecule enzyme substrate for use in methods and/or devices to electrochemically detect and/or measure LE activity in a sample.

## Claims

### Claim 1

A hydrophilic redox leukocyte esterase substrate having a chemical formula of Formula I or a pharmaceutically acceptable salt thereof:
wherein, R1 has the general structure
where R3 and R4 are independently hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl, C3 to C7 cycloalkyl, or substituted C3 to C7 cycloalkyl; R5 is independently hydrogen, saturated C1-C6 alkyl, mono-unsaturated C1-C6 alkyl, poly-unsaturated C1-C6 alkyl, C3 to C7 cycloalkyl, or substituted C3 to C7 cycloalkyl; and R6 is heterocycle or heteroaryl, wherein said heterocycle or heteroaryl is optionally substituted with 1 to 3 halogens, C1 to C3 alkyl, OH, NH2, C(O)NH2, CO2H, CH2OH, C(O)NHR′, C(O)NR′2, OR′, CH2OR′, CO2R′, NHR′, N(R′)2 or combinations therefor, where in R′ is C1 to C3 alkyl or halogenated alkyl; and
R2 is (a) the same as R1, or (b) R2 is O—R7, wherein R7 is saturated C1-C6 alkyl, mono-unsaturated C1-C6 alkyl, poly-unsaturated C1-C6, or cycloalkyl, where in the cycloakyl can be optionally substituted with 1 to 3 halogens, C1 to C3 alkyl, OH, NH2, C(O)NH2, CO2H, CH2OH, C(O)NHR″, C(O)NR″2, OR″, CH2OR″, NHR″, N(R″)2 or combinations thereof, where R″ is C1 to C3 alkyl or halogenated alkyl.

### Claim 2 (depends on 1)

The substrate of claim 1, wherein the heterocycle or heteroaryl is pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroguinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, 1,2,4-trizainyl, 1,3,5-triazinyl, isoindolyl, 1-oxoisoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, or azaindolyl.

### Claim 3 (depends on 1)

The substrate of claim 1, wherein heterocycle is aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, quinolizinyl, quinuclidinyl, 1,4-dioxaspiro[4.5]decyl, 1,4-dioxaspiro[4.4]nonyl, 1,4-dioxaspiro[4.3]octyl, or 1,4-dioxaspiro[4.2]heptyl.

### Claim 4 (depends on 1)

The substrate of claim 1, wherein the substrate is 4-{[(2S)-2-(4-methylbenzenesulfonamido)propanoyl]oxy}phenyl(2S)-2-(4-methylbenzenesulfonamido)propanoate; 4-{[(2S)-2-(pyridine-3-sulfonamido)propanoyl]oxy}phenyl (2S)-2-(pyridine-3-sulfonamido)propanoate; 4-{[(2S)-2-(6-methoxypyridine-3-sulfonamido)propanoyl]oxy}phenyl (2S)-2-(6-methoxypyridine-3-sulfonamido)propanoate; or methyl 5-{[(2S)-1-(4-{[(2S)-2-[5-(methoxycarbonyl)pyridine-3-sulfonamido]propanoyl]oxy}phenoxy)-1-oxopropan-2-yl]sulfamoyl}pyridine-3-carboxylate.

### Claim 5 (depends on 1)

A method for detecting leukocyte esterase (LE) activity comprising contacting a sample with a substrate of claim 1 forming a test sample and detecting cleavage of the substrate by LE in the test sample.

### Claim 6 (depends on 5)

The method of claim 5, wherein detecting cleavage of the substrate by LE in the test sample is by electrochemical detection.

### Claim 7 (depends on 6)

The method of claim 6, wherein electrochemical detection is by a glassy carbon electrode system.

### Claim 8 (depends on 5)

The method of claim 5, wherein the substrate concentration in the test sample is between 10 and 2000 mg/L.

### Claim 9 (depends on 1)

A reaction medium comprising a substrate of claim 1 in contact with an electrode.

### Claim 10 (depends on 9)

The reaction medium of claim 9, wherein the electrode is a carbon electrode.

### Claim 11 (depends on 9)

The reaction medium of claim 9, wherein the electrode is a glassy carbon electrode.

### Claim 12 (depends on 9)

The reaction medium of claim 9, wherein the electrode is a noble metal electrode.
